• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction.

作者信息

Mapara M Y, Körner I J, Hildebrandt M, Bargou R, Krahl D, Reichardt P, Dörken B

机构信息

Department of Internal Medicine (Medical Oncology and Tumorimmunology), Humboldt University, Virchow Klinikum-Robert Rössle Klinik, Berlin, Germany.

出版信息

Blood. 1997 Jan 1;89(1):337-44.

PMID:8978310
Abstract

We studied the efficiency of indirect tumor cell purging via enrichment of CD34+ hematopoietic progenitor cells from leukapheresis products (LP) in breast cancer patients based on immunomagnetic selection of CD34+ cells. Detection of tumor cells was made by immunocytochemical staining. In addition, we evaluated the capacity of cytokeratin 19 (CK19)- and a novel epidermal growth factor receptor (EGF-R)-specific reverse transcriptase-polymerase chain reaction (RT-PCR) for monitoring tumor cell depletion. LP from 13 breast cancer patients were analyzed. Twenty-three CD34 selection procedures were performed. A median of 1.4 x 10(10) total nucleated cells ([TNC] range, 0.88 to 3.5 x 10(10)) with a median CD34 purity of 2.5% (range, 0.4% to 6.3%) were entered into the selection procedure. Immunomagnetic CD34 enrichment resulted in a median purity of 83.3% (range, 45% to 95.4%) and a median recovery of 73.2% (range, 22% to 95%). Retransfusion of CD34-selected cells after high-dose chemotherapy resulted in a rapid and sustained hematologic recovery, reaching an absolute neutrophil count of 500/microL at day +10 and platelet count of 20,000/microL at day +11. Tumor cell depletion was quantified by immunocytochemical detection of CK19-positive cells. By this method, a median tumor cell depletion of 1.9 log (range, 0.7 to > 3 log) could be demonstrated. Immunocytochemical detection of tumor cells was more sensitive than RT-PCR, yielding positive results in 81% of LP (17 to 21) versus 58% positive LP (10 of 17). However, EGF-R-based RT-PCR was much more sensitive than CK19-based RT-PCR (10 of 17 v 1 of 17). Despite highly efficient CD34 selection, tumor cells were still detectable after CD34 enrichment using immunocytochemistry and EGF-R-specific RT-PCR. Thus, this novel EGF-R-specific RT-PCR appears to be of value as an additional method to detect contaminating breast cancer cells within LP.

摘要

相似文献

1
Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction.
Blood. 1997 Jan 1;89(1):337-44.
2
Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.在高剂量治疗后用于造血挽救的外周血祖细胞样本中,同时进行免疫磁珠法CD34+细胞分选和乳腺癌细胞清除的有效性和安全性。
Clin Cancer Res. 1999 May;5(5):1035-40.
3
Combined positive/negative purging and transplantation of peripheral blood progenitor cell autografts in breast cancer patients: a pilot study.乳腺癌患者外周血祖细胞自体移植物的正负联合净化与移植:一项初步研究。
Exp Hematol. 1999 Jan;27(1):169-75. doi: 10.1016/s0301-472x(98)00067-8.
4
Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin.在接受大剂量依托泊苷、异环磷酰胺、卡铂和表柔比星治疗后,经阳性选择的自体血CD34+细胞与未分离的外周血祖细胞介导相同的造血植入。
Blood. 1994 Sep 1;84(5):1421-6.
5
Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer.
Cytotherapy. 2001;3(2):85-95. doi: 10.1080/14653240152584578.
6
Use of reverse-transcriptase polymerase chain reaction (RT-PCR) for carcinoembryonic antigen, cytokeratin 19, and maspin in the detection of tumor cells in leukapheresis products from patients with breast cancer: comparison with immunocytochemistry.使用逆转录聚合酶链反应(RT-PCR)检测乳腺癌患者白细胞分离产物中的癌胚抗原、细胞角蛋白19和乳腺丝抑蛋白:与免疫细胞化学的比较
J Hematother. 1999 Feb;8(1):53-61. doi: 10.1089/106161299320578.
7
Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.CD34+选择、干细胞回输的不同方案以及粒细胞集落刺激因子预激对乳腺癌大剂量化疗后造血恢复的影响。
Blood. 1997 Mar 1;89(5):1521-8.
8
Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection.
Med Pediatr Oncol. 1998 Apr;30(4):228-32. doi: 10.1002/(sici)1096-911x(199804)30:4<228::aid-mpo4>3.0.co;2-i.
9
Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.多发性骨髓瘤患者外周血中浆细胞和造血祖细胞的同时动员。
J Hematother. 1996 Aug;5(4):339-49. doi: 10.1089/scd.1.1996.5.339.
10
Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation.粒细胞集落刺激因子动员的循环祖细胞的创新两步阴性选择:自体和异体移植的适用性
Blood. 1998 Mar 15;91(6):2189-96.

引用本文的文献

1
Toward Blood-Based Precision Medicine: Identifying Age-Sex-Specific Vascular Biomarker Quantities on Circulating Vascular Cells.迈向基于血液的精准医学:识别循环血管细胞上特定年龄和性别的血管生物标志物数量
Cell Mol Bioeng. 2023 Jul 6;16(3):189-204. doi: 10.1007/s12195-023-00771-1. eCollection 2023 Jun.
2
Significance of hematopoietic surface antigen CD34 in neuroblastoma prognosis and the genetic landscape of CD34-expressing neuroblastoma CSCs.造血表面抗原 CD34 在神经母细胞瘤预后中的意义和表达 CD34 的神经母细胞瘤 CSCs 的遗传特征。
Cell Biol Toxicol. 2021 Jun;37(3):461-478. doi: 10.1007/s10565-020-09557-x. Epub 2020 Sep 26.
3
Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood.
抗体偶联磁性氧化铁纳米颗粒用于新鲜全血中癌细胞的分离。
Biomaterials. 2011 Dec;32(36):9758-65. doi: 10.1016/j.biomaterials.2011.08.076. Epub 2011 Sep 14.
4
Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients.基于多重 RT-PCR 的结直肠癌患者 CEA、CK20 和 EGFR 检测。
World J Gastroenterol. 2010 Dec 21;16(47):5965-74. doi: 10.3748/wjg.v16.i47.5965.
5
Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells.正常外周血单个核细胞中 HER2 和 CK19 的低水平表达:与循环肿瘤细胞检测的相关性。
J Hematol Oncol. 2008 May 28;1:2. doi: 10.1186/1756-8722-1-2.
6
Differential interaction of magnetic nanoparticles with tumor cells and peripheral blood cells.磁性纳米颗粒与肿瘤细胞和外周血细胞的差异相互作用。
J Cancer Res Clin Oncol. 2006 May;132(5):287-92. doi: 10.1007/s00432-006-0076-x. Epub 2006 Jan 24.
7
Lack of correlation between expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients.外周血中人乳腺珠蛋白mRNA表达与乳腺癌患者已知预后因素之间缺乏相关性。
Cancer Sci. 2003 Jan;94(1):99-102. doi: 10.1111/j.1349-7006.2003.tb01359.x.
8
Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients.循环肿瘤细胞的标记基因可预测转移性乳腺癌患者的生存率。
Br J Cancer. 2003 Apr 7;88(7):1091-4. doi: 10.1038/sj.bjc.6600868.
9
Treatment of breast cancer with chemotherapy in combination with filgrastim: approaches to improving therapeutic outcome.乳腺癌化疗联合非格司亭治疗:改善治疗效果的方法。
Drugs. 2002;62 Suppl 1:17-31. doi: 10.2165/00003495-200262001-00002.
10
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.霍奇金病患者的大剂量治疗:使用选定的CD34(+)细胞与未处理的外周血祖细胞一样安全。
Bone Marrow Transplant. 2001 Nov;28(9):849-57. doi: 10.1038/sj.bmt.1703244.